Job Offer ****************************************************************************************** * Early Stage Researchers (ESR) position on CellEurope (EC FP7 ITN) project available at: ****************************************************************************************** Department of Molecular Biology and Cell Pathology Third Faculty of Medicine, Charles University Prague Ruska 87 100 00 Prague 10 Czech Republic contact: Prof. Ilona Hromadnikova ilona.hromadnikova(zavinac)lf3.cuni.cz [ MAIL "ilona.hromadnikova(zavinac)lf3.cuni.cz"] *========================================================================================= * Admission criteria *========================================================================================= • Research experience no more than 4 years • No PhD • Duration of appointment:36 months; the contract starts at latest from 1st April 2013 • Researchers must not have resided or carried out their main activity (work, studies, etc of their host organisation for more than 12 months in the 3 years immediately prior to t selection by the host institution. Short stays such as holidays are not taken into accou *========================================================================================= * CELLEUROPE Researcher Description *========================================================================================= Fellow No 6 Name ER6 Project Title GvL effects of NK cells against human leukaemia cell lines - studies Skills/Experience cell cultures, flow cytometry, ELISPOT, 51 Cr Release Assay, (STATISTICA program) Recruiting Participant (Host)UPRAGUE Duration 36 months Mentor Prof. Hromadnikova Line Manager TBC *========================================================================================= * Employment Details *========================================================================================= Planned Start Date M6 Planned End Date M42 Category ESR Actual Start Date Actual End Date Type of Contract UPRAGUE ref. Eligibility Requirements Nationality: no nationality restrictions Experience: <=4 years research experience (no PhD) *========================================================================================= * Allowances (€) *========================================================================================= Living 2666.33€ Mobility 589.40€ Monthly Salary TBC *========================================================================================= * Description of Work *========================================================================================= Active in WP 3 - Objective: Investigate expression of NK cell ligands, NK cell receptors a activity using human leukaemia blasts. ------------------------------------------------------------------------------------------ Tasks ------------------------------------------------------------------------------------------ 6.1 Investigate the in vitro PBMN cell cytotoxicity against human leukaemia cell lines fro with CML, ALL and AML during the onset and/or relapse of the disease showing high membrane positivity. 6.2 Investigate the cell surface expression NK cell ligands on the leukaemia blasts using 6.3 Investigate the cell surface expression of inhibitory and activating receptors on NK c after stimulation with hsp70 derived peptide using flow cytometry. 6.4 Investigate the stimulation of T lymphocytes, NTK cells, DC and monocytes after the pr PBMN cells with interleukins alone and in combination with hsp70 derived peptide using flo 6.5 Correlate, in collaboration with Project 7 and Project 8, cell cytotoxicity with the c expression of hsp70 and NK cell ligands on leukaemia blasts, the cell surface expression o activating receptors on NK cells and expression of activation markers on other mononuclear ------------------------------------------------------------------------------------------ Anticipated Results ------------------------------------------------------------------------------------------ a) Assessment of Hsp70 for improving the NK cell GvL effects in vitro studies b) Report on novel diagnostic and prognostic markers GvHD and GvL ------------------------------------------------------------------------------------------ Deliverables ------------------------------------------------------------------------------------------ D03.1 Assessment of hsp70 in serum samples/correlation with leukaemic blast Hsp70 expressi ------------------------------------------------------------------------------------------ Secondments ------------------------------------------------------------------------------------------ 3 months to MULTIMMUNE, SME, Germany > Hsp70 serum assessment 3 months to UNIVERSITY NEWCASTLE, UK > clinical assessment Download the position description in .docx format. [ URL "UKENG-144-version1-EarlyStage.do